Fotivda Now Available for Renal Cell Carcinoma
Fotivda is an oral vascular endothelial growth factor tyrosine kinase inhibitor.
Renal Cell Carcinoma
Belzutifan Gets Priority Review for Von Hippel-Lindau Disease-Associated RCC
Belzutifan is a potent and selective inhibitor of HIF-2α.
Fotivda Approved for Relapsed/Refractory Advanced Renal Cell Carcinoma
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
Jury Penalizes Physician for Failing to Follow Up on Abnormal Urinalysis
This month’s case addresses the issues of when to act on abnormal test results.
Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC
Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC
Biomarkers Identify Immune Checkpoint Inhibitor-Related Acute Kidney Injury
Prompt diagnosis of AKI and the ability to rule out immune checkpoint inhibitors as the cause may allow patients to continue with cancer immunotherapy.
Opdivo Plus Cabometyx Approved for Advanced Kidney Cancer
The approval was based on data from the randomized, open-label phase 3 CheckMate-9ER.
Nivolumab Plus Cabozantinib Under Review for Renal Cell Carcinoma
The applications are supported by data from the CheckMate -9ER trial that compared nivolumab, a programmed death receptor-1 blocking antibody, plus cabozantinib, a tyrosine kinase inhibitor, to sunitinib.
